Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31429056 | 0.90 | MAPT (0.54) | ARHPGDMEN1KMT2AMAPT | |
| SCHEMBL31428834 | 0.88 | GRM2 (0.48) | ARHPGDGRM2MYCMEN1 | |
| SCHEMBL31428513 | 0.88 | PDCD1 (0.53) | HPGDGRM2MEN1KMT2AMAPT | |
| SCHEMBL31429121 | 0.85 | AR (0.56) | ARHPGDGRM2CCNCCDK8 | |
| SCHEMBL31428866 | 0.85 | CCNC (0.58) | ARHPGDGRM2CCNCCDK8 | |
| SCHEMBL30163471 | 0.85 | PTK6 (0.49) | ARHPGDGRM2CCNCCDK8 | |
| SCHEMBL31428979 | 0.84 | HPGD (0.51) | HPGDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL31428537 | 0.83 | PDCD1 (0.52) | HPGDMAPTPKMKDM4EALDH1A1 | |
| SCHEMBL31428810 | 0.83 | HPGD (0.48) | HPGDMYCPKMKDM4EALDH1A1 | |
| SCHEMBL31428600 | 0.83 | AR (0.60) | ARHPGDCCNCCDK8PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | AR 1566/4885HPGD 4233/4885GRM2 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.